Parth (@flozinatorMD) header
Parth (@flozinatorMD) profile picture

PGY 7 | Internal Medicine (AIIMS, New Delhi) | Alma mater (GMC, Rajkot)

The Pale Blue Dot
Joined February 2021
Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)Photo by Parth (@flozinatorMD)
Outstanding day for Indian cricket! Immensely proud of our young cricketers for today’s impressive performance and for winning the Men’s U-19 Asia Cup 2026. Their success will inspire several youngsters. Best wishes to the team for their endeavours ahead.
𝗖.𝗛.𝗔.𝗠.𝗣.𝗜.𝗢.𝗡.𝗦 🏆 An absolutely incredible run chase in the Final gives India U19 the #MensU19AsiaCup 2026 title 🇮🇳 👏 Scorecard ▶️ bcci.tv/matches/276f2365-6b4…
854
7,482
209
48,258
1,183,598
So proud of what @batraatulonc @aiims_newdelhi is doing on so many levels! Terrific public outreach paired with innovative #clinicaltrials. Keep up the amazing work - need to find ways to integrate research with @cityofhope, @SWOG & other groups!
Most cancers are curable when diagnosed early. Know the warning signs, don't ignore symptoms that persist beyond 2–3 weeks, and get screened as advised. Grateful to @aiims_newdelhi for this #NationalCancerAwarenessDay initiative. #EarlyDetection #CancerAwareness
1
4
19
1,028
2026 Key European Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice—Commentary Based on a Virtual Focus Group clinical-breast-cancer.com/a…
1
32
97
6,501
If/when VOLGA regimen is approved, is this something (3 cycles of EV-Durva) you’d extrapolate for cis eligible MIBC patients as well and use this approach broadly or stick with EV-Pembro (EV304: and push for 9 cycles of EV)? @PGrivasMDPhD @shilpaonc @drenriquegrande @DrKarineTawagi @UroDocAsh @bergsa83 @MikeSerzanMD @BrendanGuercio #ESMO26 @tompowles1 @dr_yakupergun @DrYukselUrun
6
20
1
47
6,147
I don’t think people understand just how close we just came to a major, major incident on a cricket field. Daryl Mitchell seems to be the only one who does. #NZvIND
54
73
15
4,015
724,338
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert
2
52
3
111
6,911
👏👏 looks familiar !
𝑨 𝒎𝒐𝒏𝒖𝒎𝒆𝒏𝒕𝒂𝒍 𝒘𝒊𝒏 🇱🇰 Sri Lanka complete the second-highest chase in Men’s ODI history against England 😲 📝: icc-cricket.com/matches/2741…
82
227
12
4,244
57,400
Parth retweeted
WHAT IN THE CRICKETVERSE WAS TODAY?! 🤯
37
562
62
5,027
101,906
A game for the ages by @OfficialSLC
149
1,136
33
17,953
293,951
capecitabine
starts with C and we all love her
5
5
65
5,643
Can’t wait to read through this (while also keeping this editorial by @PTarantinoMD in mind… something that I often share with my patients in helping pick the right treatment in these settings)!
5
14
771
Parth retweeted
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. Full phase 3 evERA Breast Cancer trial results: nej.md/47ryfbF
6
48
9
132
44,268
evERA, by @elmayermd, @stolaney1 et al, is now published in NEJM. Giredestrant outperformed SoC ET when combined with everolimus in HR+/HER2- MBC, particularly in ESR1 mutant disease. Looking forward to having this highly active combo available in clinic. nejm.org/do/10.1056/NEJMdo00…
4
35
110
8,311
Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. esmoopen.com/article/S2059-7…
5
28
54
4,541
Here are the treatment algorithms we have used during our DLBCL, FL, and Mantle Cell Lymphoma discussions with @mshadman & @DrJFriedberg #Lymphoma #OncTwitter #MedTwitter @OncUpdates @OncoAlert
Treatment Algorithm discussion on Diffuse Large B-Cell lymphoma (DLBCL) with @mshadman ✅ Upfront Rx ✅ Sequencing ✅ Side effects/management Full 🗣️: ⭐️ oncbrothers.com/dlbcl-algo-2… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #HemeTwitter @OncUpdates @OncoAlert
2
25
62
6,125
Today, an @FDA advisory panel voted 7–2, with 1 abstention, that the benefits of @GrailBio Galleri multi-cancer early detection (MCED) test outweigh its risks. A closely watched milestone for the field. And if you haven’t seen it yet, the NHS-Galleri randomized trial was published yesterday in @NEJM: nejm.org/doi/abs/10.1056/NEJ…
5
26
99
13,410
don’t make fun of neurologists until you walk a myelin their shoes
63
506
29
4,107
84,893
Imlunestrant + Abema now @FDA ✅ based off EMBER-3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ mESR1 advanced BC! - Imlunestrant alone for mESR1 approved. - Combo⬆️ mPFS w/all comers (11.1mos vs 5.5mos) - If co-PIK3CA, Capi or this combo? #bcsm #OncTwitter @OncUpdates
4
29
5
70
17,269
Oh! The nostalgia!
Aravind Arora was the Zainab Vohra of our times. A Mumbai based Orthopedician who had a book for almost every subject in the now defunct AIPGMEE. His books ruled the medico bookshelves of 2000s to mid 2010s. Quite strangely, his name never had a face or even his speciality was a guess work them. I really remember well, his books were top notch. And to know he was an Ortho was truly unbelievable.
1
499
Aravind Arora was the Zainab Vohra of our times. A Mumbai based Orthopedician who had a book for almost every subject in the now defunct AIPGMEE. His books ruled the medico bookshelves of 2000s to mid 2010s. Quite strangely, his name never had a face or even his speciality was a guess work them. I really remember well, his books were top notch. And to know he was an Ortho was truly unbelievable.
27
14
3
382
23,856